CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title	Date of Registration	State
Itolizumab for Moderate-to-Severe Psoriasis-phase 3	08/10/2015	Registered
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory	09/07/2018	Registered
Phyisician Led CIMAvax-EGF lung biomarkers	11/03/2021	Registered outdated
CIMAvax-EGF in Bladder cancer	11/08/2020	Registered outdated
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab	12/05/2020	Registered outdated
CIMAvax-EGF in different maintenance schemes	12/05/2021	Registered outdated
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer	12/10/2016	Registered
CIMAvax-EGF vaccine Predictor Phase IV	14/12/2015	Registered outdated
EC122 HER-1 Prostate Phase I	15/11/2016	Registered
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients	15/12/2015	Registered
Vaxira as adjuvant treatment for non-small cell lung cancer	15/12/2015	Registered outdated
Her1 vaccine in metastatic colon and prostate cancer	16/08/2023	Registered
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors	17/02/2017	Registered
CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial	17/10/2018	Registered
Biomodulina T- CIMAvax-EGF-Advanced Non-Small Cell Lung Cancer-Adults	18/03/2021	Registered outdated
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM)	18/06/2021	Registered outdated
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders	18/06/2021	Registered outdated
NeuroEPO-Ataxia-Adults-Phase III	19/11/2020	Registered outdated
NeuroEPO in mild-moderate Alzheimer's disease	20/09/2022	Registered
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT	20/10/2021	Registered

Registered Trials

Registration process

CENTER OF MOLECULAR IMMUNOLOGY

About the RPCEC

Useful resources